First AD

Second AD

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Expert Perspectives on the Evolving Treatment Landscape of Multiple Myeloma

Peer Exchange

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

Unmet Needs and Future Perspectives in Multiple Myeloma Care

Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

Defining Frailty in Multiple Myeloma for Optimal Treatment

Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

Relapse in Multiple Myeloma: Biochemical and Chemical

Data Updates in the Treatment of Relapsed Multiple Myeloma

Strategies for Treatment of Multiple Myeloma at Late Relapse

Quadruplet Combination Therapies in Relapsed Multiple Myeloma

Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

Retreatment with a BCMA-Targeting Bispecific for R/R MM

Data Updates on Immunotherapy Combinations in Multiple Myeloma

Targets in Multiple Myeloma: GPRC5D

Targets in Multiple Myeloma: FcRH5

Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

Preventing Infection in Patients with Multiple Myeloma During Treatment

Does Belantamab Have a Place in Multiple Myeloma Treatment?